Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis

Rheumatology

Volumn 48, Issue 6, 2009, Pages 686-690

  Greenberg, Jeffrey D ^a   Harrold, Leslie R ^b   Bentley, Mary J ^b   Kremer, Joel ^c   Reed, George ^b   Strand, Vibeke ^d  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Center for Rheumatology LLP   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute phase reactants; Response criteria; Rheumatoid arthritis

Indexed keywords

ACUTE PHASE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; RHEUMATOID FACTOR;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE REGISTRY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GOLD STANDARD; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NORTH AMERICA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; ROC CURVE; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RHEUMATOLOGY; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 65849105320     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep054     Document Type: Article

References (24)

1. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
2. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
3. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 2004;364:263-9.
4. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
5. Prevoo ML, van 't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
6. van Gestel AM, Prevoo ML, van 't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
7. Zatarain E, Strand V. Monitoring disease activity of rheumatoid arthritis in clinical practice: Contributions from clinical trials. Nat Clin Pract Rheumatol 2006;2:611-8.
8. Aletaha D, Nell VPK, Stamm T et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
9. Goldman JA, Xia HA, White B et al. Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept. Ann Rheum Dis 2006;65:1649-52.
10. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 Suppl. 39):S100-8.
11. Ranganath VK, Yoon J, Elashoff DA et al. Comparison of composite measures of disease activity in an early sero-positive rheumatoid arthritis cohort. Ann Rheum Dis. Advance Access published May 21, 2007, doi.10.1136./ard.2006.065839.
12. Mierau M, Schoels M, Gonda G et al. Assessing remission in clinical practice. Rheumatology 2007;46:975-9.
13. Greenberg JD, Bingham CO, 3rd, Abramson SB et al. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Arthritis Rheum 2005;53:12-17.
14. Kremer J. The CORRONA database. Ann Rheum Dis 2005;64(Suppl.4):iV37-41.
15. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
16. Aletaha D, Ward MM, Machold KP et al. Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis Rheum 2005;52: 2625-36.
17. van Gestel AM, Anderson JJ, van Riel PL et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999;26:705-11.
18. Youden WJ. An index for rating diagnostic tests. Cancer 1950;3:32-5.
19. van Gestel AM, Haagsma CJ, Van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that included simplified joint counts. Arthritis Rheum 1998; 41:1845-50.
20. Kievit W, Fransen J, Oerlemans AJM et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473-8.
21. Aletaha D, Funovits J, Keystone EC et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35.
22. Ranganath VK, Khanna D, Paulus HE. ACR remission criteria and response criteria. Clin Exp Rheumatol 2006;24(6 Suppl. 43):S14-21.
23. Greenberg JD, Kishimoto M, Strand V et al. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Am J Med 2008;121:532-8.
24. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of antitumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003;48:313-8.